|
Delayed
London S.E.
11:34:21 2026-10-26 EDT
|
5-day change | 1st Jan Change | ||
| 3.900 GBX | +2.63% |
|
-2.50% | -37.10% |
| 10-16 | WINNERS & LOSERS: Iofina falls as output weaker than expected | AN |
| 10-08 | WINNERS & LOSERS: Kelso buys into Likewise; Litigation Capital plunges | AN |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 31.78M | - | - | - | - | - |
| 64.69B | |||||
| 54.78B | |||||
| 53.49B | |||||
| 45.98B | |||||
| 42.94B |
- Stock Market
- Stocks
- IMM Stock
- Charts ImmuPharma plc
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
